Increasing evidence exists to suggest that major depressive disorder (MDD) is associated with perturbations in the metabolism of the major excitatory and inhibitory neurotransmitters glutamate and γ-aminobutyric acid (GABA), respectively. Early studies
1,2 reported that the concentrations of glutamate/glutamine (Glx) and GABA are abnormally decreased in the plasma of patients with unipolar depression. Postmortem studies of frontal cortical
N-methyl-D-aspartate receptor complex in suicide victims
3 and of cerebrospinal fluid GABA concentrations also identified abnormalities in these systems in depression.
4,5 More recently, advances in proton magnetic resonance spectroscopy (MRS) have allowed for direct, noninvasive, in vivo measurement of cerebral Glx (measured as the combined Glx peak in the MRS spectra) and GABA concentrations in patients with mood disorders.